Last €17.45 EUR
Change Today -0.028 / -0.16%
Volume 385.0
AB3A On Other Exchanges
Symbol
Exchange
NASDAQ GS
Frankfurt
As of 9:30 AM 04/17/14 All times are local (Market data is delayed by at least 15 minutes).

sarepta therapeutics inc (AB3A) Snapshot

Open
€17.63
Previous Close
€17.48
Day High
€17.63
Day Low
€17.33
52 Week High
07/24/13 - €43.75
52 Week Low
11/13/13 - €9.32
Market Cap
659.2M
Average Volume 10 Days
1.9K
EPS TTM
--
Shares Outstanding
37.8M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for SAREPTA THERAPEUTICS INC (AB3A)

sarepta therapeutics inc (AB3A) Related Businessweek News

View More BusinessWeek News

sarepta therapeutics inc (AB3A) Details

Sarepta Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery and development of RNA-based therapeutics for the treatment of rare and infectious diseases. Its lead product candidate is Eteplirsen, an antisense PMO-based therapeutic in clinical development for the treatment of individuals with Duchenne muscular dystrophy. The company is also involved in developing treatments that are in clinical development include AVI-7288 for the treatment of Marburg virus and AVI-7100 for the treatment of influenza. In addition, it focuses on developing preclinical research product candidates for the treatment of other neuromuscular, infectious, and rare diseases. Sarepta Therapeutics, Inc. was founded in 1980 and is headquartered in Cambridge, Massachusetts.

146 Employees
Last Reported Date: 03/3/14
Founded in 1980

sarepta therapeutics inc (AB3A) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $490.0K
Chief Financial Officer, Chief Accounting Off...
Total Annual Compensation: $197.8K
Chief Medical Officer and Senior Vice Preside...
Total Annual Compensation: $364.0K
Senior Vice President, General Counsel and Co...
Total Annual Compensation: $59.9K
Vice President of Finance
Total Annual Compensation: $283.3K
Compensation as of Fiscal Year 2012.

sarepta therapeutics inc (AB3A) Key Developments

Sarepta Therapeutics, Inc. Presents at 13th Annual Needham Healthcare Conference, Apr-08-2014 12:10 PM

Sarepta Therapeutics, Inc. Presents at 13th Annual Needham Healthcare Conference, Apr-08-2014 12:10 PM. Venue: The Westin Grand Central Hotel, New York, New York, United States. Speakers: Christopher Nishan Garabedian, Chief Executive Officer, President and Director.

Sarepta Therapeutics, Inc. Presents at Boston Biotech BD Boston Conference, Mar-25-2014 through Mar-26-2014

Sarepta Therapeutics, Inc. Presents at Boston Biotech BD Boston Conference, Mar-25-2014 through Mar-26-2014. Venue: Four Seasons Hotel, 200 Boylston Street, Boston, MA 02116, United States. Presentation Date & Speakers: Mar-25-2014, Arthur M. Krieg, Chief Scientific Officer and Senior Vice President, Christopher Nishan Garabedian, Chief Executive Officer, President and Director. Mar-26-2014, Christopher Nishan Garabedian, Chief Executive Officer, President and Director.

Sarepta Therapeutics, Inc. Announces Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2013; Provides Earnings Guidance for 2014

Sarepta Therapeutics, Inc. announced earnings results for the fourth quarter and full year ended December 31, 2013. For the fourth quarter of 2013, Sarepta reported a non-GAAP net loss of $29.1 million, or $0.77 per share, compared to a non-GAAP net loss of $8.9 million for the fourth quarter of 2012, or $0.34 per share. The incremental loss is primarily the result of a $4.7 million decrease in contract revenues as well as a $15.5 million increase in non-GAAP operating expenses, due to corporate growth. On a GAAP basis, the net loss for the fourth quarter of 2013 was $8.8 million, or $0.23 per share (including $3.7 million of stock-based compensation and restructuring expenses), compared with a net loss of $62.1 million for the fourth quarter of 2012, or $2.36 per share (including $1.4 million of stock-based compensation and restructuring expenses). The decrease in net loss is the result of a $75.8 million decrease in expense incurred due to the change in valuation of the Company's outstanding warrants, offset by a $4.7 million decrease in contract revenues and a $17.8 million increase in operating expenses. Revenue for the fourth quarter of 2013 was $2.6 million, down from $7.3 million for the fourth quarter of 2012. The $4.7 million decrease was primarily due to the August 2012 stop-work-order and subsequent termination for convenience of the Ebola portion of the Ebola-Marburg U.S. government contract due to a lack of available U.S. government funding. The termination of the Ebola portion did not impact the Marburg portion of the contract. Revenues from the Marburg portion of the contract also decreased during the fourth quarter of 2013 due to the timing of activities throughout the normal progression of the contract. These decreases were partially offset by revenue from the company's European Union SKIP-NMD agreement supporting development of an exon 53 skipping therapeutic. For the year ended Dec. 31, 2013, the company’s operating loss was $90.3 million, compared to an operating loss of $29.7 million for the prior year. The $60.6 million increase was the result of a $20.5 million increase in research and development expenses and a $17.0 million increase in general and administrative expenses as well as a $23.1 million decrease in revenue from research contracts. Revenue for the year ended Dec. 31, 2013 decreased to $14.2 million from $37.3 million in 2012 primarily due to the August 2012 stop-work-order and subsequent termination of the Ebola portion of the Ebola-Marburg U.S. government contract due to lack of available U.S. government funding. For 2014, the company anticipates that loss from operations, excluding stock-based compensation, will be in the $110 to $120 million range. This guidance is largely based on continuing development and scale-up manufacturing for eteplirsen and the Company's follow-on DMD drugs, as well as increased investment in research with its platform technology.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
AB3A:GR €17.45 EUR -0.028

AB3A Competitors

Market data is delayed at least 15 minutes.

Company Last Change
AstraZeneca PLC 3,782 GBp +23.00
Baxter International Inc $72.81 USD -0.64
Gilead Sciences Inc $70.00 USD +0.72
Hemispherx Biopharma Inc $0.32 USD -0.0053
Sciclone Pharmaceuticals Inc $4.54 USD +0.07
View Industry Companies
 

Industry Analysis

AB3A

Industry Average

Valuation AB3A Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 64.5x
Price/Book 3.7x
Price/Cash Flow NM Not Meaningful
TEV/Sales 46.6x
 | 

Post a JobJobs

View all jobs

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact SAREPTA THERAPEUTICS INC, please visit www.sareptatherapeutics.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.